Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 5.55% is 44% below its 5-year average of 9.96%, near the low end of its 5-year range (5.42%–135.31%).
As of the fiscal period ended Tuesday, June 30, 2026. 88.38% below its 12-month average of 47.73%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.55%.
DEBT TO ASSETS RATIO
5.55%
DEBT TO ASSETS RATIO AVG TTM
47.73%
DEBT TO ASSETS RATIO AVG 3Y
6.96%
DEBT TO ASSETS RATIO AVG 5Y
9.96%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-88.38%
CURRENT VS 3Y AVG
-20.33%
CURRENT VS 5Y AVG
-44.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+6061.16%
vs the sector median at left
Sutro Biopharma, Inc.
Market Cap
$139.84M
Debt to Assets Ratio
5.55%
TTM Avg
47.73%
3Y Avg
6.96%
5Y Avg
9.96%
Market Cap
$139.47M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$139.04M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$137.80M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$136.67M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$136.57M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$143.60M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$143.84M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sutro Biopharma, Inc. (STRO) | $139.84M | 5.55% | 47.73% | 6.96% | 9.96% |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | 0.00% | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $139.04M | 0.02% | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.80M | 0.12% | N/A | N/A | N/A |
| Atrium Therapeutics, Inc. (RNA)vs › | $136.67M | 0.01% | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.10M | 0.31% | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $136.57M | 0.03% | N/A | N/A | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $143.60M | 0.02% | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | 0.00% | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
Debt/Assets
5.5%
Debt/Equity
N/A
Current Ratio
3.32
Interest Coverage
-2.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 5.55% |
| 2026-03-31 | 5.63% |
| 2025-12-31 | 135.31% |
| 2025-09-30 | 8.42% |
| 2025-06-30 | 83.73% |
| 2025-03-31 | 6.66% |
| 2024-12-31 | 5.98% |
| 2024-09-30 | 5.50% |
| 2024-06-30 | 5.42% |
| 2024-03-31 | 6.96% |
| 2023-12-31 | 7.15% |
| 2023-09-30 | 8.84% |
| 2023-06-30 | 10.45% |
| 2023-03-31 | 13.01% |
| 2022-12-31 | 13.52% |
| 2022-09-30 | 13.21% |
| 2022-06-30 | 14.38% |
| 2022-03-31 | 19.09% |
| 2021-12-31 | 16.81% |
| 2021-09-30 | 15.74% |
| 2021-06-30 | 6.90% |
| 2021-03-31 | 6.88% |
| 2020-12-31 | 6.23% |
| 2020-09-30 | 7.95% |
| 2020-06-30 | 8.75% |
| 2020-03-31 | 15.70% |
| 2019-12-31 | 6.32% |
| 2019-09-30 | 6.61% |
| 2019-06-30 | 6.78% |
| 2019-03-31 | 7.05% |
| 2018-12-31 | 6.60% |
| 2018-09-30 | 10.12% |
| 2018-06-30 | 32.76% |
| 2017-12-31 | 35.89% |
